Navigation Links
NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Date:8/22/2007

SAN DIEGO, Aug. 22 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President and Chief Financial Officer, is scheduled to present at the Thomas Weisel Partners Healthcare Conference at the Four Season Hotel, Boston, MA, on Thursday, September 6, 2007, at 9:45 a.m. ET.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's financial projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), ... Chief Executive Officer, Bill Welch , will be ... 2017 at 9:00 AM EDT at the Essex House ... Welch, and Chief Scientific Officer, Mark Erlander , ... during the conference.   The presentation will be ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):